 Kavita Nair
Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 6 | 2023 | 438 | 2.030 |
Why?
| | Insurance, Pharmaceutical Services | 6 | 2020 | 23 | 1.530 |
Why?
| | Drugs, Generic | 3 | 2021 | 21 | 1.430 |
Why?
| | Managed Care Programs | 6 | 2014 | 133 | 1.430 |
Why?
| | Chronic Disease | 6 | 2020 | 1720 | 1.040 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 3 | 2022 | 73 | 0.960 |
Why?
| | Prescription Drugs | 2 | 2021 | 112 | 0.950 |
Why?
| | Health Resources | 2 | 2016 | 114 | 0.830 |
Why?
| | Choice Behavior | 2 | 2020 | 168 | 0.790 |
Why?
| | Cost Sharing | 3 | 2020 | 14 | 0.780 |
Why?
| | Nervous System Diseases | 2 | 2023 | 251 | 0.750 |
Why?
| | Insurance Benefits | 3 | 2010 | 11 | 0.750 |
Why?
| | Retinal Degeneration | 1 | 2021 | 34 | 0.710 |
Why?
| | Drug Costs | 1 | 2021 | 100 | 0.670 |
Why?
| | Health Services | 2 | 2009 | 99 | 0.580 |
Why?
| | Health Expenditures | 5 | 2017 | 180 | 0.540 |
Why?
| | Medicare Part D | 2 | 2021 | 26 | 0.530 |
Why?
| | Insurance Coverage | 2 | 2011 | 219 | 0.480 |
Why?
| | Hospital Costs | 1 | 2016 | 115 | 0.470 |
Why?
| | Hydrochlorothiazide | 1 | 2014 | 9 | 0.470 |
Why?
| | Hypertension | 2 | 2014 | 1243 | 0.470 |
Why?
| | Chlorthalidone | 1 | 2014 | 7 | 0.470 |
Why?
| | Patient Admission | 1 | 2016 | 183 | 0.450 |
Why?
| | Practice Patterns, Physicians' | 2 | 2021 | 1271 | 0.440 |
Why?
| | Insurance, Health | 3 | 2016 | 267 | 0.430 |
Why?
| | Tetrazoles | 1 | 2013 | 38 | 0.420 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2013 | 36 | 0.420 |
Why?
| | Immunologic Factors | 2 | 2015 | 230 | 0.420 |
Why?
| | Antihypertensive Agents | 2 | 2014 | 485 | 0.410 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2012 | 338 | 0.400 |
Why?
| | Gout Suppressants | 1 | 2012 | 17 | 0.400 |
Why?
| | Fibric Acids | 1 | 2012 | 3 | 0.390 |
Why?
| | Arthritis, Gouty | 1 | 2012 | 14 | 0.390 |
Why?
| | Acute Coronary Syndrome | 1 | 2016 | 267 | 0.390 |
Why?
| | Imidazoles | 1 | 2013 | 234 | 0.390 |
Why?
| | Drug Labeling | 1 | 2012 | 41 | 0.380 |
Why?
| | Absenteeism | 1 | 2012 | 47 | 0.380 |
Why?
| | Health Care Costs | 2 | 2012 | 367 | 0.380 |
Why?
| | Off-Label Use | 1 | 2012 | 51 | 0.380 |
Why?
| | Inpatients | 1 | 2016 | 475 | 0.370 |
Why?
| | Hospital Mortality | 1 | 2016 | 848 | 0.370 |
Why?
| | Medicare | 2 | 2024 | 708 | 0.360 |
Why?
| | United States | 14 | 2024 | 13871 | 0.350 |
Why?
| | Retrospective Studies | 15 | 2024 | 14522 | 0.350 |
Why?
| | Diagnostic Tests, Routine | 1 | 2011 | 104 | 0.330 |
Why?
| | Blood Pressure | 2 | 2014 | 1736 | 0.330 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2012 | 430 | 0.320 |
Why?
| | Middle Aged | 19 | 2024 | 31136 | 0.320 |
Why?
| | Health Benefit Plans, Employee | 1 | 2009 | 22 | 0.310 |
Why?
| | Antibodies, Monoclonal | 3 | 2012 | 1366 | 0.310 |
Why?
| | Adrenal Cortex Hormones | 1 | 2012 | 524 | 0.300 |
Why?
| | Autoimmune Diseases | 1 | 2012 | 427 | 0.300 |
Why?
| | Dyslipidemias | 2 | 2012 | 177 | 0.300 |
Why?
| | Program Development | 1 | 2010 | 355 | 0.290 |
Why?
| | Humans | 34 | 2024 | 129627 | 0.290 |
Why?
| | Loratadine | 2 | 2005 | 4 | 0.280 |
Why?
| | Male | 23 | 2024 | 63671 | 0.280 |
Why?
| | Diabetes Mellitus | 3 | 2017 | 1001 | 0.270 |
Why?
| | Female | 23 | 2024 | 68735 | 0.270 |
Why?
| | Nonprescription Drugs | 2 | 2005 | 66 | 0.260 |
Why?
| | Adult | 17 | 2024 | 35600 | 0.260 |
Why?
| | Antirheumatic Agents | 1 | 2009 | 280 | 0.260 |
Why?
| | Models, Economic | 2 | 2016 | 53 | 0.240 |
Why?
| | Drug Prescriptions | 3 | 2005 | 248 | 0.240 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2023 | 757 | 0.230 |
Why?
| | Stiff-Person Syndrome | 1 | 2024 | 11 | 0.230 |
Why?
| | Infusions, Intravenous | 2 | 2023 | 399 | 0.230 |
Why?
| | Lupus Vasculitis, Central Nervous System | 1 | 2024 | 14 | 0.230 |
Why?
| | Neurofilament Proteins | 1 | 2024 | 43 | 0.220 |
Why?
| | Aged | 14 | 2024 | 22061 | 0.220 |
Why?
| | Aquaporin 4 | 1 | 2024 | 95 | 0.220 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2024 | 91 | 0.220 |
Why?
| | Insurance Claim Review | 3 | 2017 | 64 | 0.220 |
Why?
| | Neurology | 2 | 2023 | 103 | 0.210 |
Why?
| | Negotiating | 1 | 2024 | 30 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2014 | 2011 | 0.210 |
Why?
| | Natalizumab | 2 | 2015 | 40 | 0.210 |
Why?
| | Prescription Fees | 1 | 2003 | 4 | 0.210 |
Why?
| | Neuromyelitis Optica | 1 | 2024 | 129 | 0.210 |
Why?
| | Quality Indicators, Health Care | 1 | 2005 | 298 | 0.210 |
Why?
| | Young Adult | 8 | 2024 | 12455 | 0.190 |
Why?
| | Patient Outcome Assessment | 1 | 2023 | 126 | 0.190 |
Why?
| | Information Services | 1 | 2001 | 47 | 0.190 |
Why?
| | Metabolic Networks and Pathways | 1 | 2022 | 177 | 0.190 |
Why?
| | Myeloid Cells | 1 | 2022 | 142 | 0.180 |
Why?
| | Neurologists | 1 | 2021 | 20 | 0.180 |
Why?
| | Community Participation | 1 | 2001 | 125 | 0.170 |
Why?
| | Atrophy | 1 | 2021 | 169 | 0.170 |
Why?
| | Infliximab | 2 | 2012 | 101 | 0.170 |
Why?
| | Rituximab | 1 | 2021 | 164 | 0.170 |
Why?
| | Arthritis, Rheumatoid | 1 | 2009 | 1098 | 0.170 |
Why?
| | Dementia | 1 | 2023 | 225 | 0.170 |
Why?
| | Attitude to Health | 1 | 2003 | 433 | 0.160 |
Why?
| | Patient Satisfaction | 1 | 2003 | 633 | 0.150 |
Why?
| | Cohort Studies | 4 | 2013 | 5426 | 0.140 |
Why?
| | Cost-Benefit Analysis | 4 | 2024 | 569 | 0.140 |
Why?
| | Adolescent | 7 | 2024 | 20412 | 0.140 |
Why?
| | B-Lymphocytes | 1 | 2022 | 816 | 0.140 |
Why?
| | Pharmaceutical Services | 2 | 2011 | 81 | 0.130 |
Why?
| | Protein Kinase Inhibitors | 1 | 2022 | 887 | 0.130 |
Why?
| | Models, Statistical | 1 | 2020 | 625 | 0.130 |
Why?
| | Drug Utilization Review | 3 | 2005 | 57 | 0.120 |
Why?
| | Medication Adherence | 2 | 2010 | 558 | 0.120 |
Why?
| | Ambulatory Care | 2 | 2023 | 506 | 0.110 |
Why?
| | Systole | 1 | 2014 | 191 | 0.110 |
Why?
| | Losartan | 1 | 2013 | 14 | 0.110 |
Why?
| | Valsartan | 1 | 2013 | 27 | 0.110 |
Why?
| | Formularies as Topic | 2 | 2003 | 6 | 0.100 |
Why?
| | Linear Models | 1 | 2016 | 819 | 0.100 |
Why?
| | Drug Substitution | 1 | 2013 | 51 | 0.100 |
Why?
| | Valine | 1 | 2013 | 81 | 0.100 |
Why?
| | Biphenyl Compounds | 1 | 2013 | 60 | 0.100 |
Why?
| | Aged, 80 and over | 4 | 2016 | 7052 | 0.100 |
Why?
| | Biomarkers | 1 | 2024 | 3968 | 0.100 |
Why?
| | Population Surveillance | 1 | 2016 | 439 | 0.100 |
Why?
| | Contraindications | 1 | 2012 | 90 | 0.100 |
Why?
| | Gemfibrozil | 1 | 2012 | 11 | 0.100 |
Why?
| | Simvastatin | 1 | 2012 | 60 | 0.100 |
Why?
| | Costs and Cost Analysis | 1 | 2012 | 201 | 0.090 |
Why?
| | Hypolipidemic Agents | 1 | 2012 | 92 | 0.090 |
Why?
| | Mitoxantrone | 1 | 2011 | 14 | 0.090 |
Why?
| | Age Distribution | 1 | 2012 | 373 | 0.090 |
Why?
| | Glatiramer Acetate | 1 | 2011 | 18 | 0.090 |
Why?
| | Prevalence | 3 | 2024 | 2564 | 0.090 |
Why?
| | Hematologic Tests | 1 | 2011 | 22 | 0.090 |
Why?
| | Colorado | 3 | 2024 | 4404 | 0.090 |
Why?
| | United States Food and Drug Administration | 1 | 2012 | 205 | 0.090 |
Why?
| | Financing, Personal | 1 | 2011 | 26 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2017 | 566 | 0.090 |
Why?
| | Interferon-beta | 1 | 2011 | 89 | 0.090 |
Why?
| | Poisson Distribution | 1 | 2010 | 73 | 0.090 |
Why?
| | Length of Stay | 1 | 2016 | 1122 | 0.090 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 94 | 0.090 |
Why?
| | Likelihood Functions | 1 | 2010 | 137 | 0.080 |
Why?
| | Spine | 1 | 2011 | 160 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2014 | 10219 | 0.080 |
Why?
| | Severity of Illness Index | 2 | 2017 | 2739 | 0.080 |
Why?
| | Patient Discharge | 1 | 2016 | 836 | 0.080 |
Why?
| | Preferred Provider Organizations | 1 | 2009 | 4 | 0.080 |
Why?
| | Quality-Adjusted Life Years | 2 | 2024 | 106 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2012 | 1293 | 0.080 |
Why?
| | Respiratory Function Tests | 1 | 2011 | 581 | 0.080 |
Why?
| | Orthopedic Procedures | 1 | 2011 | 209 | 0.080 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 1042 | 0.080 |
Why?
| | Transportation | 1 | 2009 | 50 | 0.080 |
Why?
| | Private Sector | 1 | 2009 | 50 | 0.080 |
Why?
| | Regression Analysis | 2 | 2009 | 997 | 0.080 |
Why?
| | Pain Management | 1 | 2011 | 324 | 0.080 |
Why?
| | North America | 1 | 2009 | 292 | 0.070 |
Why?
| | Incidence | 2 | 2024 | 2641 | 0.070 |
Why?
| | Electrocardiography | 1 | 2011 | 611 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 5415 | 0.070 |
Why?
| | Research Design | 1 | 2014 | 1045 | 0.070 |
Why?
| | Proportional Hazards Models | 1 | 2011 | 1198 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2012 | 1202 | 0.070 |
Why?
| | Electronic Health Records | 1 | 2014 | 973 | 0.070 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1499 | 0.070 |
Why?
| | Program Evaluation | 1 | 2010 | 875 | 0.060 |
Why?
| | Patient Acceptance of Health Care | 1 | 2012 | 761 | 0.060 |
Why?
| | Peptides | 1 | 2011 | 926 | 0.060 |
Why?
| | Logistic Models | 1 | 2010 | 1986 | 0.060 |
Why?
| | Time Factors | 1 | 2016 | 6555 | 0.060 |
Why?
| | Anti-Allergic Agents | 1 | 2005 | 45 | 0.060 |
Why?
| | Efficiency, Organizational | 1 | 2005 | 133 | 0.060 |
Why?
| | Benchmarking | 1 | 2005 | 176 | 0.060 |
Why?
| | Follow-Up Studies | 1 | 2013 | 4894 | 0.060 |
Why?
| | Histamine H2 Antagonists | 1 | 2004 | 29 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 358 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2720 | 0.050 |
Why?
| | Neuroglia | 1 | 2024 | 163 | 0.050 |
Why?
| | Hyperlipidemias | 1 | 2003 | 126 | 0.050 |
Why?
| | Patient Compliance | 2 | 2003 | 565 | 0.050 |
Why?
| | Pamphlets | 1 | 2001 | 23 | 0.050 |
Why?
| | Hypoglycemic Agents | 1 | 2010 | 1221 | 0.050 |
Why?
| | Decision Making | 2 | 2015 | 863 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2005 | 712 | 0.050 |
Why?
| | Health Care Surveys | 1 | 2023 | 557 | 0.050 |
Why?
| | Risk Assessment | 1 | 2010 | 3262 | 0.040 |
Why?
| | Students, Pharmacy | 1 | 2001 | 96 | 0.040 |
Why?
| | Hospitalization | 1 | 2009 | 2057 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3394 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 5075 | 0.040 |
Why?
| | Child | 3 | 2024 | 20884 | 0.040 |
Why?
| | Recurrence | 1 | 2020 | 1011 | 0.030 |
Why?
| | Models, Econometric | 1 | 2017 | 33 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3628 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2024 | 3378 | 0.030 |
Why?
| | Neurons | 1 | 2024 | 1494 | 0.030 |
Why?
| | Registries | 1 | 2023 | 1899 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2017 | 712 | 0.030 |
Why?
| | Medical Audit | 1 | 2013 | 74 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1213 | 0.020 |
Why?
| | Diabetes Complications | 1 | 2014 | 224 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2015 | 398 | 0.020 |
Why?
| | Sex Factors | 1 | 2017 | 1970 | 0.020 |
Why?
| | Databases, Factual | 1 | 2016 | 1269 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2015 | 1365 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 3152 | 0.020 |
Why?
| | Comorbidity | 1 | 2014 | 1547 | 0.020 |
Why?
| | Rhinitis, Allergic, Perennial | 1 | 2005 | 23 | 0.010 |
Why?
| | California | 1 | 2005 | 400 | 0.010 |
Why?
| | Child, Preschool | 1 | 2016 | 10490 | 0.010 |
Why?
| | Coronary Disease | 1 | 2003 | 385 | 0.010 |
Why?
| | Risk Factors | 1 | 2003 | 9786 | 0.010 |
Why?
|
|
Nair's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|